French multinational pharmaceutical and healthcare company Sanofi announced a partnership with New York-based TrialSpark, which offers a technology-based model for drug development.
TrialSpark's tools aim for more efficient trial design, faster trial completion and higher quality trial data. It acquires clinical-stage drugs from pharmaceutical and biotech companies and develops them using its...
TrialSpark, a health tech platform that lets providers become clinical trial sites, scored a whopping $156 million as part of a Series C funding round to start developing its own molecular treatments.
This round, which was led by Sam Altman and Lachy Groom, with participation from Sequoia Capital, Thrive Capital, Casdin Capital, Dragoneer, Section 32, John Doerr, Spark Capital, Felicis Ventures,...
23andMe, a frontrunner in the consumer genomics space, is turning its attention to clinical trial recruitment. The company has inked a deal with TrialSpark, a health tech platform that lets providers become clinical trial sites, connecting their customers to the latter’s trial network.
The new deal will use 23andMe’s crowdsourced research platform, which lets its customers opt into research and...
